Market Currents
Shares of Halozyme (HALO) shoot up 29% premarket after the firm announces positive results from...
-
Tuesday, October 18, 2011, 8:00 AM ETShares of Halozyme (HALO) shoot up 29% premarket after the firm announces positive results from a Phase 3 HannaH trial of its breast cancer treatment, Herceptin, given by subcutaneous injection.
Other date
Latest Articles